|
WO2021050885A1
|
|
Neurological disease treatment with complement inhibitors
|
|
WO2020247607A1
|
|
Inflammatory disease treatment with complement inhibitors
|
|
WO2020219822A1
|
|
Compositions and methods for modulating complement activity
|
|
WO2020205501A1
|
|
Complement modulators and related methods
|
|
TW202100179A
|
|
Modulators of complement activity
|
|
TW202034943A
|
|
Neurological disease treatment with complement inhibitors
|
|
WO2019246386A1
|
|
Cyclic polypeptides for pcsk9 inhibition
|
|
EP3810177A1
|
|
Cyclic polypeptides for pcsk9 inhibition
|
|
US2021000927A1
|
|
Modulators of complement activity
|
|
WO2019051436A1
|
|
Formulations for compound delivery
|
|
WO2018106859A1
|
|
Modulators of complement activity
|
|
WO2017181061A1
|
|
Ras binding peptides and methods of use
|
|
CN108697759A
|
|
The conditioning agent of complement activity
|
|
EP3250230A1
|
|
Modulators of complement activity
|
|
CA2949985A1
|
|
Modulation of complement activity
|
|
EP2850095A1
|
|
Peptide and peptidomimetic inhibitors
|
